Abstract Search

ea0056p754 | Neuroendocrinology | ECE2018

Initiation of tolvaptan therapy for mild/moderate chronic SIADH-induced hyponatremia in a day-ward

Ramos Elvira , Barrio Elvira , Miguel Paz de , Cuesta Martin , Fernandez Luzdivina , Victoria Saez de Parayuelo Maria , Maria Cruz Anba , Ortiz Marta , Calle Alfonso , Runkle Isabelle

Introduction: Tolvaptan is the only V2-receptor antagonist authorized for use in Europe in patients with SIADH. Its initiation requires hospitalization. Our goal was to analyze the safety and efficacy of tolvaptan started in a Hospital Day-Ward.Material and methods: Retrospective descriptive study of 33 ambulatory patients with mild/moderate SIADH-induced chronic sustained hyponatremia initiating tolvaptan therapy in the Day-Ward of a tertiary center ove...

0 shares

ea0073ep5 | Adrenal and Cardiovascular Endocrinology | ECE2021

Acquired hypoaldosteronism as classified by circulating aldosterone levels: characteristics

Jorge Gabriel Ruiz Sánchez , Mario Pazos , Xavier Perez Candel , Martín Cuesta Hernández , Emilia Gomez Hoyos , Maria Paz De Miguel Novoa , Victoria Saez de Parayuelo , Alfonso Calle , Isabel Runkle

Acquired Hypoaldosteronism may be caused by low circulating aldosterone levels (AD), resistance to mineralocorticoid action (MR), or a combination of both (CB). We describe the clinical/biochemical characteristics of these three types of hypoaldosteronism. Methods Retrospective review of a series of 177 patients with acquired hypoaldosteronism assessed by the Endocrinology Department of a tertiary teaching hospital from 2012 to 201...

6 shares

Endocrine Abstracts

Initiation of tolvaptan therapy for mild/moderate chronic SIADH-induced hyponatremia in a day-ward

Acquired hypoaldosteronism as classified by circulating aldosterone levels: characteristics

BiosciAbstracts